BME:MAPInsurance
Mapfre (BME:MAP) Stock Valuation After 2024 Results Show Premium Growth And Better Non Life Margins
Mapfre (BME:MAP) drew investor focus after releasing its 2024 income statement, highlighting expected premium growth of 6.6% at constant exchange rates and a Non-Life combined ratio of 94.4%, compared with 97.2% in 2023.
See our latest analysis for Mapfre.
That backdrop has kept investors' attention on the stock, which has a 12.4% 90 day share price return but is down 3.2% year to date. The 1 year total shareholder return of 28.9% points to momentum that has built over a longer stretch.
If...